Benjamin D Nordhues1, Konstantinos C Siontis1, Christopher G Scott2, Vuyisile T Nkomo3, Michael J Ackerman4,3,5, Samuel J Asirvatham4,3, Peter A Noseworthy3. 1. Department of Medicine, Windland Smith Rice Sudden Death Genomics Laboratory Mayo Clinic, Rochester, Minnesota, USA. 2. Division of Biostatistics, Windland Smith Rice Sudden Death Genomics Laboratory Mayo Clinic, Rochester, Minnesota, USA. 3. Division of Cardiovascular Diseases, Windland Smith Rice Sudden Death Genomics Laboratory Mayo Clinic, Rochester, Minnesota, USA. 4. Division of Pediatric Cardiology, Department of Pediatrics, Windland Smith Rice Sudden Death Genomics Laboratory Mayo Clinic, Rochester, Minnesota, USA. 5. Department of Molecular Pharmacology and Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory Mayo Clinic, Rochester, Minnesota, USA.
Abstract
INTRODUCTION: Bileaflet mitral valve prolapse (BiMVP) is common among survivors of otherwise unexplained sudden cardiac death, but prognostic implications of BiMVP are unknown. This study evaluated whether patients with BiMVP are at higher risk for ventricular dysrhythmias, ICD placement, or death compared to controls with either single-leaflet mitral valve prolapse (SiMVP) or no mitral valve prolapse (MVP). METHODS AND RESULTS: This retrospective, matched cohort study included 18,786 patients who underwent echocardiography at Mayo Clinic between June 1990 and September 2014. The study included three cohorts: BiMVP, SiMVP, and controls without MVP. We assessed rates of ventricular dysrhythmias, ICD placement, and all-cause mortality between groups. BiMVP was associated with higher rates of ventricular tachycardia compared to SiMVP and controls (adjusted HR 1.48 [1.14-1.92], P = 0.003 and 1.40 [1.04-1.88], P = 0.026, respectively); however, there were no statistically significant differences in rates of ventricular fibrillation/cardiac arrest or ICD placement between groups. BiMVP was associated with a lower rate of all-cause mortality compared to SiMVP and controls (adjusted HR 0.86 [0.79-0.94], P = 0.0008, and 0.55 [0.50-0.60], P < 0.0001, respectively). CONCLUSION: Although BiMVP is associated with ventricular tachycardia, it is not associated with an increased risk of cardiac arrest/ventricular fibrillation or ICD implantation and is, paradoxically, associated with a better survival compared to SiMVP or matched controls. The findings suggest that, despite its association with ventricular tachycardia, BiMVP in the absence of other risk factors does not seem to portend a poor prognosis at the population level.
INTRODUCTION:Bileaflet mitral valve prolapse (BiMVP) is common among survivors of otherwise unexplained sudden cardiac death, but prognostic implications of BiMVP are unknown. This study evaluated whether patients with BiMVP are at higher risk for ventricular dysrhythmias, ICD placement, or death compared to controls with either single-leaflet mitral valve prolapse (SiMVP) or no mitral valve prolapse (MVP). METHODS AND RESULTS: This retrospective, matched cohort study included 18,786 patients who underwent echocardiography at Mayo Clinic between June 1990 and September 2014. The study included three cohorts: BiMVP, SiMVP, and controls without MVP. We assessed rates of ventricular dysrhythmias, ICD placement, and all-cause mortality between groups. BiMVP was associated with higher rates of ventricular tachycardia compared to SiMVP and controls (adjusted HR 1.48 [1.14-1.92], P = 0.003 and 1.40 [1.04-1.88], P = 0.026, respectively); however, there were no statistically significant differences in rates of ventricular fibrillation/cardiac arrest or ICD placement between groups. BiMVP was associated with a lower rate of all-cause mortality compared to SiMVP and controls (adjusted HR 0.86 [0.79-0.94], P = 0.0008, and 0.55 [0.50-0.60], P < 0.0001, respectively). CONCLUSION: Although BiMVP is associated with ventricular tachycardia, it is not associated with an increased risk of cardiac arrest/ventricular fibrillation or ICD implantation and is, paradoxically, associated with a better survival compared to SiMVP or matched controls. The findings suggest that, despite its association with ventricular tachycardia, BiMVP in the absence of other risk factors does not seem to portend a poor prognosis at the population level.
Authors: Antonio Oliva; Vincenzo M Grassi; Oscar Campuzano; Maria Brion; Vincenzo Arena; Sara Partemi; Monica Coll; Vincenzo L Pascali; Josep Brugada; Angel Carracedo; Ramon Brugada Journal: Int J Legal Med Date: 2016-09-21 Impact factor: 2.686
Authors: Bulent Gorenek; John D Fisher; Gulmira Kudaiberdieva; Adrian Baranchuk; Haran Burri; Kristen Bova Campbell; Mina K Chung; Andrés Enriquez; Hein Heidbuchel; Valentina Kutyifa; Kousik Krishnan; Christophe Leclercq; Emin Evren Ozcan; Kristen K Patton; Win Shen; James E Tisdale; Mohit K Turagam; Dhanunjaya Lakkireddy Journal: J Interv Card Electrophysiol Date: 2019-12-11 Impact factor: 1.900
Authors: Francesca N Delling; Sidney Aung; Eric Vittinghoff; Shiktij Dave; Lisa J Lim; Jeffrey E Olgin; Andrew Connolly; Ellen Moffatt; Zian H Tseng Journal: JACC Clin Electrophysiol Date: 2021-02-24
Authors: Hui-Chen Han; Francis J Ha; Andrew W Teh; Paul Calafiore; Elizabeth F Jones; Jennifer Johns; Anoop N Koshy; David O'Donnell; David L Hare; Omar Farouque; Han S Lim Journal: J Am Heart Assoc Date: 2018-12-04 Impact factor: 5.501